Antibacterials Drugs: Prescriptive Appropriety in the Covid-19 Emergency

Abstract

The new coronavirus disease 2019 (COVID-19) is a highly contagious zoonosis produced by SARS-CoV-2, it is spread from human to human via respiratory secretions. It is a public health emergency that has strained health systems around the world and could also have negative implications for the fight against antimicrobial resistance. As we well know, during the first months of the pandemic, empirical therapies with antibiotics were conducted, especially in hospitals, for patients suffering from coronavirus infection, this is a fact that has opened a great debate, especially for the risks of antibiotics resistance. From the medical records analyzed, today it appears that over 90% of patients with Covid-19 receive empiric antibiotic therapy, this because, in these months of emergency, attention to this phenomenon was not a priority. Among the negative effects of the pandemic on the fight against hospital infections we must also consider the overload of the diagnostic laboratories, which has made the work on the surveillance of pathogens harder.